Job posting

For employers: Reach the most qualified candidates by posting your job opening on ISCaM web site free of chargeThis service is reserved only to ISCaM members. Log in to begin managing your job posting and  click on "Content" in the top menu. Announcements can be academic posts or grant-funded research posts which are relevant to the field of cancer metabolism.

 

For jobseekers: Access the newest and freshest jobs available to professionals seeking employment by registering to the ISCaM web site.

 

  • Postdoctoral fellows

    Posted: 
    Monday, 15 May 2017
    Expires: 
    Monday, 15 May 2017
    The Molecular Oncology group directed by Prof. Alimonti at the University of Padova-V.I.M.M. is seeking two Postdoctoral fellows.
     
    Alimonti lab is interested in understanding how the tumor immune response regulates senescence activation or evasion in cancer. A major focus of the lab is the development of immunotherapeutic strategies for the clinic. We are looking for highly motivated researchers with a PhD or equivalent degree. Applicants with a strong background in senescence, signaling in cancer and tumor immunology are encouraged to apply. We offer excellent working conditions: a 
    competitive salary, state-of-the art facilities and direct access to clinically relevant human samples from patients enrolled in international trials in prostate cancer.
     
    Specific projects include:
     
    1. Screening and optimization of pro-senescence and senolytic compounds for cancer therapy
     
    2. Characterization of the role of the innate and adaptive immunity in senescent tumors
     
    3. Generation of new mouse model for prostate cancer
     
    Candidate requirements
     
    •Ph.D or M.D./Ph.D. (already obtained or soon to be)
    •At least one first author publication in a relevant journal
    •Highly motivated person with strong interest in research
    •Experience using mouse models and/or generation of mouse model is highly desirable.
     
    For inquiry regarding this job please contact Monica Montopoli via E-mail: monica.montopoli@unipd.it
     
    Complete applications, inclusive of curriculum vitae, two references, and short description of previous training and work experiences should be sent by mail or email to the following address: monica.montopoli@unipd.it
     
    Our selected recent publications:
     
    Di Mitri et al. Nature, 2014
     
    Revandkar et.al Nature Communications 2016
     
    Khalatur et al. Nature Communications, 2015
     
    Toso et al. Cell Reports, 2014
     
    Alajati et al. Cell Reports, 2015
     
    Alimonti et al. Nature Genet, 2010

     

    Qualifications: 
    Ph.D or M.D./Ph.D. (already obtained or soon to be)
    Salary: 
    contact Monica Montopoli for more details (monica.montopoli@unipd.it)
    Employers: 
    University of Padova
    Job type: 
    PostDoc fellow
  • Early Stage Researcher (ESR/PhD) in the Marie Skłodowska-Curie ITN European Training Network “TRANSMIT – TRANSlating the role of Mitochondria in Tumorigenesis” (H2020-MSCA-ITN-2016) - ESR 6 (Karolinska Institutet, Sweden)

    Posted: 
    Wednesday, 12 April 2017
    Expires: 
    Friday, 30 June 2017

    TRANSMIT - TRANSlating the role of Mitochondria in Tumorigenesis

    The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical evidence places mitochondria as key actors in cancer metabolic restructuring, not only because these organelles have a crucial role in the energy and biosynthetic intermediates production but also because mutations in metabolic enzymes encoded by both nuclear and mitochondrial DNA have been associated with different types of cancer. TRANSMIT aims to dissect the metabolic remodeling in human cancers, placing the focus on the role of mitochondria and bridging basic research to the improvement/development of therapeutic strategies. Further, TRANSMIT fosters the communication of this emerging field to the patients and their families. To meet these aims, TRANSMIT has formed a network throughout seven countries, and consisting of world-leading basic science and clinical centers of excellence, several industrial partners with up-todate omics technologies, as well as non-profit foundations and associations who care for cancer patients. By creating a critical mass of scientific excellence, TRANSMIT will allow transfer of current knowledge into the wide field of cancer research, translating scientific and technical advances into the education and training of eleven Early Stage Researchers. TRANSMIT will implement training-through-research dedicated to unraveling the metabolic features of cancer, as well as providing a full portfolio of complementary skills through the creation of a network of basic, translational and industrial laboratories devoted to a multidisciplinary/multisectorial education of young scientists.

     

    Project Description

    1) Job Summary: Within the training program provided by the TRANSMIT consortium, the candidate will have his/her training at the Karolinska Institutet, Sweden, and will be employed there as a Research Assistant, but will be enrolled as a PhD student in the 3-year PhD program in General Medical Sciences at the University of Bologna (UNIBO), Italy. UNIBO will thus provide the envisaged PhD degree.

    The candidate will in a research lab environment design and carry out analyses of mitochondrial involvement and function in cancer-related clinical samples as well as in cultured cells in vitro, and relate the results to clinically and biologically relevant factors such as patient outcome data and mechanisms of chemoresistance. Lab work includes setting up routines for sample handling, cell cultures and performing cell-based assays. The candidate will also contact and interact with clinicians, pathologists, companies, biostatisticians etc. The tasks thus include thorough and rational planning, monitored by supervisor(s), accurate and neat hands-on work in the lab, and clear presentation of results. The program also includes courses and secondments with other members of the TRANSMIT network. As science and knowledge are based on communicable data and ideas, organizational as well as communication skills will be emphasized and further trained. The candidate will be required to spend a six-month period in Italy.

    2) Job description: Ovarian cancer (OC) is the deadliest gynecological cancer, making it the fifth leading cause of cancer deaths in women. Even if treatment (surgery + platinum-based chemotherapy) is initially successful, many patients relapse within 6 months into disseminated disease; highly chemoresistant so-called cancer stem cells are believed to underlie this development. Risk factors include obesity and/or diabetes type 2 (DM2). Both have been associated with increased risk as well as poorer outcome and survival in OC. Risk and/or poorer outcome appear to involve altered levels of cyto- and adipokines secreted by obese adipose tissue. See review by Craig et al., Gyn Oncol 2016.

    The candidate will examine: (a) molecular mechanisms of resistance to platinum chemotherapy in cultured OC cells, with focus on how mitochondria and cellular metabolism differ in resistant and sensitive cells, e.g., mitochondrial morphology and dynamics, and which metabolic pathways are involved in platinum resistance and/or cancer stem cell features; (b) the role(s) of regulators of mitochondrial biogenesis and function, e.g., the transcriptional co-regulator PGC1, in regulation of metabolism, chemoresistance and/or cancer stem cell features in OC, e.g., using in vitro knockdown of expression; (c) effects of selected cytokines and adipokines on mitochondria and chemoresistance in cultured OC cells, and correlation of cyto-/adipokine levels in patient samples with clinical data such as clinical resistance, survival time, BMI etc; (d) expression levels of PGC1 and presence of cancer-associated adipocytes in patient samples, and correlations with clinical data.

    Lab methods include western blotting, ELISAs, PCR methods, cellular viability assays, metabolic assays (e.g., ATP measurements, oxygen consumption, lactate production) and metabolic marker profiling, confocal microscopy, knockdown methods, immunohistochemistry. Results are expected to be of publication quality.

    Communication skills are practiced under supervision in the form of manuscript writing, poster presentations, student seminars and all other types of interaction with other professionals and students. Courses include Oncology and Tumor Biology comprising both clinical and preclinical knowledge, Biostatistics and 1-2 courses of the candidate´s choice in consultation with the supervisor.

    The profile of the research environment of the Department of Oncology-Pathology at the Karolinska Institutet is translational, i.e., it supports the translation of preclinical research into clinically useful knowledge. The research group of Dr. Shoshan has a long-standing interest in cancer cell metabolism and tumor progression, and collaboration with clinicians, pathologist as well as biostatisticians. The Department will in the spring of 2018 move to new premises built to promote interaction between different research groups and interests.

    3) Subject area of PhD program in which the ESR will be enrolled and PhD program duration: PhD in General Medical Sciences – 3 years

    4) Host University that will provide the PhD degree: Department of Medical and Surgical Sciences - University of Bologna, Italy

    5) PhD program starting date: November 1st 2017

     

    Required Educational Level

    Degree: An M.Sc. degree in Biomedicine or similar Life Science discipline, with emphasis on Cell Biology or Tumor Biology, also a good grounding in Biochemistry.

    Degree Field: Biomedicine or similar Life Science discipline, with emphasis on Cell Biology or Tumor Biology, also a good grounding in Biochemistry.

    Skills: Excellent communication skills

    Languages: Applicant should be fluent in written and spoken English

     

    Applications, in English, should include a CV, detailed academic transcripts in the form of certified copies of all undergraduate level certificates, a certified copy of the M.Sc. thesis or similar, a list of research-related methodological skills that the applicant is proficient in, a list of training experiences abroad (e.g. Erasmus project, Mobility fellowship, Leonardo project), a motivation letter and a reference letter, which are all to be submitted by email to Dr. Maria Shoshan, at mimmi.shoshan@ki.se

     

    Application deadline: June 30th 2017

     

    *Eligibility: The applicants must be in possession of a degree in Biomedicine or similar Life Science disciplines at the date of recruitment at the date of recruitment - an ‘early stage researcher’ (i.e. in the first four years of his/her research career and not have a doctoral degree).

     

    The applicant may be a national of a Member State, of an Associated Country or of any other Third Country.

    The applicants may not have resided in the country where the research training activities take place (i.e. not in Sweden) for more than 12 months in the 3 years immediately prior to the recruitment date and may not have carried out their main activity (work, studies, etc.) in that country.

     

    Benefits

    ·         Enrollment in a PhD school in a specific area

    ·         3-year employment contract: taxable salary (SEK 25,800/month + €600/month converted to SEK at payment) for 36 months that entitles to Swedish social security benefits.

    ·         A highly multidisciplinary, cross-cultural and competitive training program in the field of metabolism in cancer and molecular oncology

    ·         Secondments and a specific training program

    ·         25 vacation days/year.

     

    Selection criteria

    First selection step: Curriculum evaluation. Numerical scores will be awarded for grading criteria such as study marks, duration of study, scientific publications in peer reviewed journals, reference letters. Only the admitted candidates will be contacted by e-mail for the second selection step.

    Second selection step: A Skype interview in which candidates will give a short presentation of their master thesis and of a scientific paper that they will receive three weeks before the interview.

    Third selection step: A face-to-face interview with the top two candidates. Travelling costs will be entirely at the candidates’ expense. 

    Qualifications: 
    Degree: An M.Sc. degree in Biomedicine or similar Life Science discipline, with emphasis on Cell Biology or Tumor Biology, also a good grounding in Biochemistry; Degree Field: Biomedicine or similar Life Science discipline, with emphasis on Cell Biology o
    Salary: 
    SEK 25,800/month + €600/month (converted to SEK at payment)
    Employers: 
    Karolinska Institutet, Stockholm, Sweden
    Job type: 
    Temporary: 3-year employment contract
    Location: 
    Stockholm, Sweden
    Contact: 
    Dr. Maria Shoshan (mimmi.shoshan@ki.se)
  • Early Stage Researcher (ESR/PhD) in the Marie Skłodowska-Curie ITN European Training Network “TRANSMIT – TRANSlating the role of Mitochondria in Tumorigenesis” (H2020-MSCA-ITN-2016) - ESR 5 (University of Bologna, DIMEC, Italy)

    Posted: 
    Tuesday, 11 April 2017
    Expires: 
    Sunday, 18 June 2017

    TRANSMIT - TRANSlating the role of Mitochondria in Tumorigenesis

    The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical evidences place mitochondria as key actors in cancer metabolic restructuring, not only because these organelles have a crucial role in the energy and biosynthetic intermediates production but also because occurrence of mutations in metabolic enzymes encoded by both nuclear and mitochondrial DNA has been associated to different types of cancer. TRANSMIT aims to dissect the metabolic remodeling in human cancers, placing the focus on the role of mitochondria and bridging basic research to the improvement/development of therapeutic strategies. Further, TRANSMIT fosters the communication of this emerging field to the patients and their families. To these aims, TRANSMIT will create a network of seven different countries, among which world-leading basic science and clinical centers of excellence, several industrial partners with up-todate omics technologies, as well as non-profit foundations and associations who care for cancer patients. By creating the critical mass of scientific excellence, TRANSMIT will allow to transfer the current knowledge into the wide field of cancer research, translating scientific and technical advances into the education and training of eleven Early Stage Researchers. TRANSMIT will implement training-through-research dedicated to unravel the metabolic features of cancer, as well as to provide a full portfolio of complementary skills through the creation of a network of basic, translational and industrial laboratories, devoted to a multidisciplinary/multisectorial education of young scientists.

     

    Project Description

    1) Job Summary. The candidate will be enrolled in a PhD program to work in molecular oncology, learning and exploiting molecular genetics and biology techniques, to generate and characterize cancer cell models targeted for metabolic and tumor suppressor proteins, and test them for modifications in their tumorigenic potential, both in vitro and in nude mice models. Starting from the knowledge of the oncojanus function for respiratory complex I genes, the candidate will investigate the synthetic lethality of other molecular targets with such genes. In collaboration with other consortium partners and through secondments, the candidate will acquire knowledge of specific techniques to tackle the issues proposed. Collateral skills will be developed during the 3-years fellowship, such as grant and paper writing, fund raising abilities, outreach and dissemination in the field of molecular oncology.

     

    2) Job description: Application refers to an Early Stage Researcher (ESR) position to be trained for 36 months at the Department of Medical and Surgical Sciences, University of Bologna, in the framework of the TRANSMIT project entitled “Mitochondrial complex I-driven regulation of the hypoxic response in cancer cells” (ESR 5). Supervisor: Prof. Giuseppe Gasparre.

    Adaptation to hypoxia is one of the main features of aggressive cancer cells, a process mediated by the hypoxia-inducible factor 1α (HIF1α). During oxygen shortage, HIF1α becomes stabilized following inhibition of α-ketoglutarate (α-KG)-dependent prolyl-hydroxylases (PHDs). Therefore, α-KG levels are critical in the cell capacity to respond to hypoxia through HIF1α, which acts as a key transcription factor to transcribe a large set of genes involved in the upregulation of glycolysis, promotion of neoangiogenesis and metastasis. In turn, α-KG dehydrogenase (α-KGDH) is regulated by NADH levels, the main substrate of CI. Tumors in which CI is mutated and disassembled, such as benign oncocytomas, are unable to respond to hypoxia and progress to malignancy due to their lack of NADH consumption and consequent accumulation of α-KG. To translate these findings into a potential adjuvant therapeutic strategy, and to deeply dissect the biochemical mechanisms linking CI disruption to hypoxia adaptation, the candidate will use genome editing approaches such as Zinc Finger Nucleases or CRISPR technology to generate knock-out (KO) clones for CI subunit NDUFS3, essential to assemble CI, starting from cancer cell models such as osteosarcoma 143B, colon HCT116 and ovary SKOV-3, whose growth kinetics in nude mice are known. The candidate will hence characterize clones for NADH and α-KG accumulation following CI disruption and will attempt to reconstruct the metabolic routes used by the KO clones to survive, via metabolomics analyses. The candidate will exploit a hypoxic chamber to challenge KO clones to forcedly respond to hypoxia and will assess by western blot whether they are able to trigger HIF1α stabilization. Clones will be challenged for their anchorage-independent growth ability in soft agar, and subsequently the candidate will proceed to observe whether KO clones are able to form xenografts in nude mice. The hypoxia level of xenograft will be evaluated with pimonidazole, whereas HIF1α stabilization in vivo will be assessed by immunohistochemistry and western blot. Moreover, the candidate will have available a syngenic HCT116 cell line devoid of tumor suppressor TP53, whose role in mitochondrial metabolism regulation is well known to act through TP53-induced glycolysis and apoptosis regulator and respiratory complex IV (31). The candidate will obtain NDUFS3 knock-out of p53-null HCT116 to compare with p53-competent HCT116, to unravel the metabolic rewiring occurring in the absence of a pivotal tumor suppressor gene. The candidate will attempt to understand whether the anti-tumorigenic effect of NDUFS3 KO may be overcome by the abolishment of p53.

    3) Subject area of PhD program in which the ESR will be enrolled and PhD program duration: Medical, Pharmaceutical and Veterinary Medical Sciences; PhD in General Medical Sciences (duration 3 year)

    4) Host University that will provide the PhD degree: Università di Bologna, Italy- Department of Medical and Surgical Sciences.

    5) PhD program starting date: November 1st 2017

     

    Required Educational Level

    Degree: Biology, Biotechnology, Genetics, Biochemistry, Medicine

    Degree Field: Human Molecular Biology, Human Biology, Human Molecular Genetics, Human Genetics

    Skills: Basic molecular biology and genetics techniques

     

    Languages: Applicant should be fluent in written and spoken English

     

    Applications, in English, should include CV, detailed academic transcripts, the abstract of the thesis (300 words max), a motivation letter, a reference letter and the application form, which are all to be submitted by email to Prof. Giuseppe Gasparre (fabit.transmit@unibo.it). Applicants are required to indicate both the title and the number of the project as the object of the e-mail (they are both mentioned in the "Job description" section).

    Application deadline: June 18th 2017

    The application form can be download from the following webpage: https://euraxess.ec.europa.eu/jobs/199795 by clicking on the "WHERE TO APPLY” section.

     

    Eligibility requirements

    The applicant may be a national of a Member State, of an Associated Country or of any other Third Country.

     

    Career:           At the time of recruitment, applicants are to  have academic qualifications to  access a PhD position and have to be in their first four years of their research careers and have not been awarded with a doctoral degree.

     

    Applicants are required to have less than 4 years of full time research experience.

     

    Mobility:          At the time of recruitment, Applicants must not have resided in Italy for more than 12 months in the 3 years immediately prior to the recruitment date and not have carried out their main activity (work, studies, etc.) in that country.

     

    Benefits

    ·         Enrollment in a PhD school in a specific area

    ·         The selected candidate will be appointed under a 36-month full-time employment contract according to the Italian national legislation. The remuneration will be compliant with the rules of the ITN-MSCA Program. The gross amount for the benefit of the researcher includes:

    a)       Monthly living allowance: the amount is € 3,318.37 per month.

    b)      Mobility allowance: the amount is € 600,00 per month (€ 7.200,00/year).

    c)       Family allowance: a Family allowance of €500 per month will be paid to researcher with family. Family” is defined as persons linked to the researcher by (i) marriage, or (ii) a relationship with equivalent status to a marriage recognised by the national or relevant regional legislation of the country where this relationship was formalised; or (iii) dependent children who are actually being maintained by the researcher. The family status of a researcher will be determined at the time of their (first) recruitment in the project and will not evolve during the project lifetime.

    The net amount results from deducting all compulsory social security contributions as well as direct taxes from the gross amount.

    ·         A highly multidisciplinary, cross-cultural and competitive training program in the field of metabolism in cancer and molecular oncology

    ·         Secondments and a specific training program

    ·         Vacation days/year: 30 days/year in addition to November 1, December 8-25-26, January 1, 6, April 25, May 1, June 2. Easter and Easter Monday (they change each year)

     

    Selection criteria

    First selection step: Curriculum evaluation. Numerical scores will be awarded for grading criteria such as study marks, duration of study, scientific publications in peer reviewed journals, reference letters. Only the admitted candidates will be contacted by e-mail for the second selection step.

    Second selection step: Skype or face-to-face interview in which candidates will give a short presentation of their master thesis and of a scientific paper that they will receive three weeks before the interview.

     

    Evaluation period:

    Two weeks during September / October 2017

    Qualifications: 
    Degree: Biology, Biotechnology, Genetics, Biochemistry, Medicine; Degree Field: Human Molecular Biology, Human Biology, Human Molecular Genetics, Human Genetics
    Salary: 
    Gross amount of € 3,318.37 per month + € 600,00 per month of mobility allowance + €500 per month of family allowance (if applicable)
    Employers: 
    Department of Medical and Surgical Sciences, University of Bologna, Italy
    Job type: 
    Temporary: 3-year employment contract
    Location: 
    Bologna, Italy
    Contact: 
    Prof. Giuseppe Gasparre (fabit.transmit@unibo.it)
  • Early Stage Researcher (ESR/PhD) in the Marie Skłodowska-Curie ITN European Training Network “TRANSMIT – TRANSlating the role of Mitochondria in Tumorigenesis” (H2020-MSCA-ITN-2016) – ESR 9 (University of Bologna, Dept. FaBiT, Italy)

    Posted: 
    Tuesday, 11 April 2017
    Expires: 
    Sunday, 18 June 2017

    TRANSMIT - TRANSlating the role of Mitochondria in Tumorigenesis

    The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical evidences place mitochondria as key actors in cancer metabolic restructuring, not only because these organelles have a crucial role in the energy and biosynthetic intermediates production but also because occurrence of mutations in metabolic enzymes encoded by both nuclear and mitochondrial DNA has been associated to different types of cancer. TRANSMIT aims to dissect the metabolic remodeling in human cancers, placing the focus on the role of mitochondria and bridging basic research to the improvement/development of therapeutic strategies. Further, TRANSMIT fosters the communication of this emerging field to the patients and their families. To these aims, TRANSMIT will create a network of seven different countries, among which world-leading basic science and clinical centers of excellence, several industrial partners with up-todate omics technologies, as well as non-profit foundations and associations who care for cancer patients. By creating the critical mass of scientific excellence, TRANSMIT will allow to transfer the current knowledge into the wide field of cancer research, translating scientific and technical advances into the education and training of eleven Early Stage Researchers. TRANSMIT will implement training-through-research dedicated to unravel the metabolic features of cancer, as well as to provide a full portfolio of complementary skills through the creation of a network of basic, translational and industrial laboratories, devoted to a multidisciplinary/multisectorial education of young scientists.

     

    Project Description

    1) Job Summary. The candidate will be enrolled in a PhD program to work in cellular and molecular biology, learning and exploiting biochemical, molecular and biology techniques. Starting from the knowledge of the interplay between respiratory complex I and HIF1a, the candidate will investigate how the unbalance of αKG/SA ratio can mimic a normoxic condition causing HIF1α destabilization, and thus, prevents hypoxic adaptation and metabolic reprogramming. In collaboration with other consortium partners and through secondments, the candidate will acquire knowledge of specific techniques to tackle the issues proposed. Collateral skills will be developed during the 3-year fellowship, such as grant and paper writing, fund raising abilities, outreach and dissemination in the field of molecular oncology.

     

    2) Job description: Application refers to an Early Stage Researcher (ESR) position to be trained for 36 months at the Department of Pharmacy and Biotechnology, University of Bologna, in the framework of the TRANSMIT project entitled “Inducing pseudonormoxia as adjuvant therapeutic strategy for cancer” (ESR 9). Supervisor: Prof. Anna Maria Porcelli.

    It has been demonstrated that complex I-defective cancer cells display an increased α-KG/SA ratio that activates PHDs and leads to a pseudonormoxic state where HIF1α is destabilized even during hypoxia. Thus, CIdeficient cancer cells are not able to acquire a HIF1α-dependent Warburg profile and their tumorigenic potential is markedly inhibited both in vitro and in vivo. These findings highlight a functional link between HIF1α stabilization and mitochondrial function opening to new therapeutic approaches for most solid cancers. Hence, the idea of a metabolic-based approach as adjuvant therapy represents a promising strategy against cancer, whose malignant progression is supported by adaptation to a hypoxic environment. In this context, ESR will prove that cell-permeable α-KG ester derivatives prevent tumor progression by inducing a pseudonormoxic state specifically in cancer cells. To achieve this goal, ESR will collect a panel of cancer and non-cancer primary cell lines deriving from the same tissue. Since 2D monolayer cell cultures are not representative of the complexity of 3D solid tumors, ESR will generate 3D culture models that will be characterized in terms of mitochondrial function, HIF1α status and tumorigenic features in vitro. Then, the toxicity of an already available library of fifteen cell-permeable α-KG ester derivatives will be evaluated. The effect of these compounds on PHDs activity and HIF1α stabilization and activation will be determined. Moreover, ESR will prove the ability of α-KG derivatives previously selected to modulate xenografts formation after injection of cancer cell lines in nude mice.

    3) Subject area of PhD program in which the ESR will be enrolled and PhD program duration: Biological, Geological and Agricultural Sciences; PhD in Cellular and Molecular Biology (duration 3 year)

    4) Host University that will provide the PhD degree: Università di Bologna, Italy- Department of Pharmacy and Biotechnology.

    5) PhD program starting date: November 1st 2017

     

    Required Educational Level

    Degree: Degree/Master Degree in Biology, Biochemistry and Biotechnology

    Degree Field: Human Cellular and Molecular Biology, Human Biochemistry, Human Molecular Genetics

    Skills: Proven working experience in a research lab, proficiency in basic techniques in biochemistry, cell and molecular

    Languages: Applicant should be fluent in written and spoken English

     

    Applications, in English, should include CV, detailed academic transcripts, the abstract of the thesis (300 words max), a motivation letter, a reference letter and the application form, which are all to be submitted by email to Prof. Anna Maria Porcelli (fabit.transmit@unibo.it). Applicants are required to indicate both the title and the number of the project as the object of the e-mail (they are both mentioned in the "Job description" section).

    Application deadline: June 18th 2017

    The application form can be download from the following webpage: https://euraxess.ec.europa.eu/jobs/199746 by clicking on the "WHERE TO APPLY” section.

     

    Eligibility requirements

    The applicant may be a national of a Member State, of an Associated Country or of any other Third Country.

     

    Career:           At the time of recruitment, applicants are to  have academic qualifications to  access a PhD position and have to be in their first four years of their research careers and have not been awarded with a doctoral degree.

     

    Applicants are required to have less than 4 years of full time research experience.

                                                 

    Mobility:         At the time of recruitment, Applicants must not have resided in Italy for more than 12 months in the 3 years immediately prior to the recruitment date and not have carried out their main activity (work, studies, etc.) in that country.

     

    Benefits

    ·         Enrollment in a PhD school in a specific area

    ·         The selected candidate will be appointed under a 36-month full-time employment contract according to the Italian national legislation. The remuneration will be compliant with the rules of the ITN-MSCA Program. The gross amount for the benefit of the researcher includes:

    a)       Monthly living allowance: the amount is € 3,318.37 per month.

    b)      Mobility allowance: the amount is € 600,00 per month (€ 7.200,00/year).

    c)       Family allowance: a Family allowance of €500 per month will be paid to researcher with family. Family” is defined as persons linked to the researcher by (i) marriage, or (ii) a relationship with equivalent status to a marriage recognised by the national or relevant regional legislation of the country where this relationship was formalised; or (iii) dependent children who are actually being maintained by the researcher. The family status of a researcher will be determined at the time of their (first) recruitment in the project and will not evolve during the project lifetime.

    The net amount results from deducting all compulsory social security contributions as well as direct taxes from the gross amount.

    ·         A highly multidisciplinary, cross-cultural and competitive training program in the field of metabolism in cancer and molecular oncology

    ·         Secondments and a specific training program

    ·         Vacation days/year: 30 days/year in addition to November 1, December 8-25-26, January 1, 6, April 25, May 1, June 2. Easter and Easter Monday (they change each year)

     

     

    Selection criteria

    First selection step: Curriculum evaluation. Numerical scores will be awarded for grading criteria such as study marks, duration of study, scientific publications in peer reviewed journals, reference letters. Only the admitted candidates will be contacted by e-mail for the second selection step.

    Second selection step: Skype or face-to-face interview in which candidates will give a short presentation of their master thesis and of a scientific paper that they will receive three weeks before the interview.

     

    Evaluation period

    Two weeks during September / October 2017

    Qualifications: 
    Degree/Master: Degree in Biology, Biochemistry and Biotechnology; Degree Field: Human Cellular and Molecular Biology, Human Biochemistry, Human Molecular Genetics
    Salary: 
    Gross amount of € 3,318.37 per month + € 600,00 per month of mobility allowance + €500 per month of family allowance (if applicable)
    Employers: 
    Department of Pharmacy and Biotechnology, University of Bologna, Italy
    Job type: 
    Temporary: 3-year employment contract
    Location: 
    Bologna, Italy
    Contact: 
    Prof. Anna Maria Porcelli (fabit.transmit@unibo.it).
  • Early Stage Researcher (ESR/PhD) in the Marie Skłodowska-Curie ITN European Training Network “TRANSMIT – TRANSlating the role of Mitochondria in Tumorigenesis” (H2020-MSCA-ITN-2016) - ESR 1 (University of Bordeaux, France)

    Posted: 
    Friday, 7 April 2017
    Expires: 
    Monday, 31 July 2017

    TRANSMIT - TRANSlating the role of Mitochondria in Tumorigenesis

    The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical evidences place mitochondria as key actors in cancer metabolic restructuring, not only because these organelles have a crucial role in the energy and biosynthetic intermediates production but also because occurrence of mutations in metabolic enzymes encoded by both nuclear and mitochondrial DNA has been associated to different types of cancer. TRANSMIT aims to dissect the metabolic remodeling in human cancers, placing the focus on the role of mitochondria and bridging basic research to the improvement/development of therapeutic strategies. Further, TRANSMIT fosters the communication of this emerging field to the patients and their families. To these aims, TRANSMIT will create a network of seven different countries, among which world-leading basic science and clinical centers of excellence, several industrial partners with up-to-date omics technologies, as well as non-profit foundations and associations who care for cancer patients. By creating the critical mass of scientific excellence, TRANSMIT will allow to transfer the current knowledge into the wide field of cancer research, translating scientific and technical advances into the education and training of eleven Early Stage Researchers. TRANSMIT will implement training-through-research dedicated to unravel the metabolic features of cancer, as well as to provide a full portfolio of complementary skills through the creation of a network of basic, translational and industrial laboratories, devoted to a multidisciplinary/multi-sectorial education of young scientists.

     

    Project Description

    1)                  Job Summary

    This PH.D project will be performed in the research team directed by Dr. Rodrigue ROSSIGNOL, INSERM U1211, at the university of Bordeaux in France. The project focuses on the study on lung tumors metabolic reprogramming and bioenergetics based on preliminary findings from our laboratory Briefly, we analyzed a consistent number of surgical pieces of freshly excised human lung adenocarcinoma using bioenergetics and Omics technologies and discovered the existence of two subgroups of lung tumors characterized by a high or a low respiration, that we denominated “Ox+‟ and “Ox-‟, respectively (publication in preparation). The Ph.D trainee will study the molecular determinants of lung tumors metabolic reprograming, with a particular emphasis of oxidative tumors. Cell and mouse models of human adenocarcinoma available in the laboratory will be used to verify the role of specific signaling pathways and environmental triggers identified in the preliminary study. This PhD project includes the identification and the validation of relevant target(s) for developing anti-cancer metabolic strategies against oxidative lung tumors. Those genetic and pharmacological approaches will be evaluated at preclinical stage on orthotopic mouse models of human oxidative adenocarcinoma. Altogether, this project aims at a better understanding of lung tumors heterogeneity with implication for the development of adapted therapies.

     

    2)                  Job description

    The PH.D candidate will analyze cell culture models of human adenocarcinoma of variegated bioenergetic profile and perform cell proteomic, cell biology, cell signaling, transcriptomic and bioenergetic experiments to decipher the determinants of the oxidative profile of lung tumors subgroup. Gene invalidation studies using shRNA or CRISPR will be conducted on those cells to delineate the role of transcription factors and kinase already identified in our preliminary studies. Those experiments will also be conducted in mouse (orthotopic model) to verify the impact of target gene invalidation / pharmacological modulation on tumor growth and survival but also metastasis and resistance to chemotherapy. Proof-of-concept and proof-of-mechanisms experiments should be generated during this project. Metabolic reprogramming of lung adenocarcinoma cells and their corresponding mouse tumors will further be deciphered using metabolomics, in collaboration with METATOOL platform (Toulouse; France). The bioenergetic analyses will be performed in collaboration with CELLOMET, a technology platform associated to our academic laboratory. As part of TRANSMIT, the PhD candidate will perform additional training in partners laboratories during the course of his/her PhD: mtDNA mutation in OX+ versus OX- tumors (Bologna, Italy); metastatic potential of OX+ versus OX- cells (Brussels; Belgium); Chemo-resistance of OX+ versus OX- cells (Stockholm; Sweden).

    Subject area of PhD program in which the ESR will be enrolled and PhD program duration

    Ph.D in Biochemistry (3 years).

    3)                  Host University that will provide the PhD degree

    University of Bordeaux (Bordeaux; France)

    4)                  PhD program starting date: 01/10/17

     

    Required Educational Level

    Degree:  Master.

    Degree Field: Biochemistry / Cell Biology / Molecular Pathophysiology

    Skills:

    Knowledge: good level in biochemistry, cell signaling, mitochondrial physiology and energy metabolism pathways. Good notions in cancer biology and in lung physiology are also required.

    Methods: cell culture (mammalian cells), siRNA/shRNA transfection, lentiviral plasmids production/transduction, polarography, fluorescence microscopy, westernblot, immunoprecipitation, immunocyto/histo-chemistry, Omics sample preparation and data analysis (IPA software…). Experience in mouse models of cancer is appreciated: tumor size follow-up by bioluminescence imaging, drug/cells injection, necropsy and tissue sampling for histology, proteomics and biochemical analyses.

    Personality: strong motivation in cancer research, autonomy and respect of other team members.

    Languages:                                        

    Applicant should be fluent in written and spoken English

     

    Applications, in English, should include CV, detailed academic transcripts, a copy of the thesis, a motivation letter and a reference letter, which are all to be submitted by email to rodrigue.rossignol@u-bordeaux.fr

     

    *Elegibility: The applicants must be in possession of a degree in Biochemistry or Cell Biology and Molecular Physiology at the date of recruitment - an ‘early stage researcher’ (i.e. in the first four years of his/her research career and not have a doctoral degree).

     

    The applicant may be a national of a Member State, of an Associated Country or of any other Third Country.

    The applicant should not have resided in the country where the research training activities take place for more than 12 months in the 3 years immediately prior to the recruitment date and not have carried out their main activity (work, studies, etc.) in that country.

     

    Benefits

    ·                    Enrollment in a PhD school in a specific area

    ·                    3-year employment contract: net salary of 3253 euros + 416 euros net of family allowance (if applicable)

    ·                    A highly multidisciplinary, cross-cultural and competitive training program in the field of metabolism in cancer (or molecular oncology)

    ·                    Secondments and a specific training program

    ·                    Vacation days/year:

     

    Selection criteria

    First selection step: Curriculum evaluation. Numerical scores will be awarded for grading criteria such as study marks, duration of study, scientific publications in peer reviewed journals, reference letters. Only the admitted candidates will be contacted by e-mail for the second selection step.

    Second selection step: Skype or face-to-face interview in which candidates will give a short presentation of their master thesis and of a scientific paper that they will receive three weeks before the interview.

     

    Evaluation period: none.

    Qualifications: 
    Masters level Degree in Biochemistry / Cell Biology / Molecular Pathophysiology
    Salary: 
    Net monthly salary of 3253 euros + 416 euros net of family allowance (if applicable)
    Employers: 
    University of Bordeaux – Inserm U1211, University Hospital, Bordeaux, France
    Job type: 
    Temporary: 3-year employment contract
    Location: 
    Bordeaux, France
    Contact: 
    Rodrigue Rossignol (rodrigue.rossignol@u-bordeaux.fr)
  • Early Stage Researcher (PhD student) in Cancer Metabolism (Pierre Sonveaux Lab)

    Posted: 
    Friday, 24 March 2017
    Expires: 
    Friday, 30 June 2017

    ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

    H2020-MSCA-ITN-2016

    Early Stage Researcher (ESR/PhD)

     

    TRANSMIT - TRANSlating the role of Mitochondria in Tumorigenesis

    The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical evidences place mitochondria as key actors in cancer metabolic restructuring, not only because these organelles have a crucial role in the energy and biosynthetic intermediates production but also because occurrence of mutations in metabolic enzymes encoded by both nuclear and mitochondrial DNA has been associated to different types of cancer. TRANSMIT aims to dissect the metabolic remodeling in human cancers, placing the focus on the role of mitochondria and bridging basic research to the improvement/development of therapeutic strategies. Further, TRANSMIT fosters the communication of this emerging field to the patients and their families. To these aims, TRANSMIT will create a network of seven different countries, among which world-leading basic science and clinical centers of excellence, several industrial partners with up-todate omics technologies, as well as non-profit foundations and associations who care for cancer patients. By creating the critical mass of scientific excellence, TRANSMIT will allow to transfer the current knowledge into the wide field of cancer research, translating scientific and technical advances into the education and training of eleven Early Stage Researchers. TRANSMIT will implement training-through-research dedicated to unravel the metabolic features of cancer, as well as to provide a full portfolio of complementary skills through the creation of a network of basic, translational and industrial laboratories, devoted to a multidisciplinary/multisectorial education of young scientists.

    Project Description

    Job Summary

    The PhD student will conduct experimental research in the field of tumor metabolism. He/she will lead his/her own research program under the direction of Prof. Pierre Sonveaux and the direct supervision of a post-doc, with the assistance of a lab technician.

    Job description

    In primary tumors, natural selection is known to foster the emergence of metastatic progenitor cells. Because its thorough understanding could ultimately be translated in treatments aimed to prevent metastasis, the metastatic switch is the subject of intense investigation. In previous work, we tested whether mitochondrial metabolism could promote tumor metastasis. We identified two different metabolic alterations, a TCA cycle overload and bottlenecking of the mitochondrial electron transport chain (ETC), which trigger tumor cell migration, invasion, clonogenicity, metastatic take and, overall, spontaneous metastasis (Porporato PE et al., Cell Reports 2014;8:754-766). We further found that these pro-metastatic phenotypic features are primarily conferred by an enhanced mitochondrial production of mtROS in both systems, and can be countered with mitochondria-targeted ROS scavengers. For the open position, using our well established models, the PhD student will aim to identify the exact nature of mtROS promoting tumor metastasis, their molecular origin and the signaling pathways by which altered mitochondria drive the metastatic process. The combination of specific sensors, scavengers, antioxidants and RNA interference will allow him/her to discriminate specific activities of superoxide from that of H2O2. Mitochondrial dysfunctions will be traced back to mtDNA and ETC complexes abnormalities. Altered expression/activity of specific enzymes and proteins known to regulate TCA cycle and the coupling between ETC activity and ATP synthesis will be investigated. Finally, based on early evidence indicating that focal adhesion kinase (FAK) family member Pyk2 executes at least in part the metastatic program triggered by mtROS, the PhD student will further characterize the activation of the mtROS-FAK axis in metastatic cancer cells, its inhibition by mtROS scavengers, and the consequences of its inhibition on the metastatic program in vitro and in vivo.

    Subject area of PhD program in which the ESR will be enrolled and PhD program duration

    PhD in Biomedical and Pharmaceutical Sciences (3 years)

    Host University that will provide the PhD degree

    Université catholique de Louvain (UCL)

    PhD program starting date

    October 1st, 2017

    Required Educational Level

    Degree: Master in Life Sciences

    Degree Field: Pharmaceutical Sciences, Biomedical Sciences, Medicine, Biology and related fields

    Skills: Good theoretical knowledge of Biochemistry in Oncology. Practical knowledge will be a plus. Applicants should demonstrate interest for anticancer research and their motivation to be integrated in an international research team.

    Languages:  Applicant should be fluent in written and spoken English.

     

    Applications, in English, should include CV, detailed academic transcripts, a summary of the thesis (abstract), a motivation letter and a reference letter, which are all to be submitted as a single PDF file by email to c.remacle@uclouvain.be  

     

    *Eligibility: The applicants must be in possession of a Master degree at the date of recruitment - an ‘early stage researcher’ (i.e., in the first four years of his/her research career and not have a doctoral degree).

     

    The applicant must be a national of an EU Member State, of an Associated Country or of any other Third Country as defined by the European Commission

    The applicants  not have resided in the country where the research training activities take place for more than 12 months in the 3 years immediately prior to the recruitment date and not have carried out their main activity (work, studies, etc.) in that country.

     

    Benefits

    ·         3-year employment contract (38 h/week) with a possibility of extension for a 4th year.

    ·         Enrollment in a PhD school of Biochemical and Pharmaceutical Sciences (DFAR).

    ·         A highly multidisciplinary, international and competitive training program in the field of metabolism in cancer.

    ·         Secondments and a specific training programs at other host institutions that are member of the  Marie Skłodowska-Curie grant agreement No 722605 - TRANSMIT

    ·         Vacation days/year: 24

     

    Selection criteria

    First selection step: Curriculum evaluation. Numerical scores will be awarded for grading criteria such as study marks, duration of study, scientific publications in peer reviewed journals, reference letters. Only the admitted candidates will be contacted by e-mail for the second selection step.

    Second selection step: Phone, skype or face-to-face interview in which candidates will give a short presentation of their master thesis and of a scientific paper that they will receive three weeks before the interview.

     

    Qualification: Master in Pharmaceutical Sciences, Biomedical Sciences, Medicine, Biology and related fields

    Salary: 23.000 EUR per annum + a mobility allowance of 7,200 Euro per annum

    Employer: Université Catholique de Louvain (UCL), Brussels, Belgium

    Job type: temporary: 3-year employment contract

    Location: Brussels, Belgium

    Contact: Claude Remacle (c.remacle@uclouvain.be)

    Deadline for application: 30 June 2017

    Evaluation period: 15 July 2017

    ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

    Qualifications: 
    Master in Life Sciences
    Salary: 
    30200 EUR/year
    Employers: 
    Université catholique de Louvain (UCL)
    Job type: 
    PhD student, Research Assistant
    Location: 
    Brussels
    Contact: 
    c.remacle@uclouvain.be
    Qualifications: 
    The applicant must be a national of an EU Member State, of an Associated Country or of any other Third Country as defined by the European Commission
  • Early Stage Researcher (ESR/PhD) in the Marie Skłodowska-Curie ITN European Training Network “TRANSMIT – TRANSlating the role of Mitochondria in Tumorigenesis” (H2020-MSCA-ITN-2016) – ESR 8 (AvantiCell Science Ltd, UK)

    Posted: 
    Monday, 20 March 2017
    Expires: 
    Wednesday, 31 May 2017

    TRANSMIT - TRANSlating the role of Mitochondria in Tumorigenesis

    The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical evidences place mitochondria as key actors in cancer metabolic restructuring, not only because these organelles have a crucial role in the energy and biosynthetic intermediates production but also because occurrence of mutations in metabolic enzymes encoded by both nuclear and mitochondrial DNA has been associated to different types of cancer. TRANSMIT aims to dissect the metabolic remodeling in human cancers, placing the focus on the role of mitochondria and bridging basic research to the improvement/development of therapeutic strategies. Further, TRANSMIT fosters the communication of this emerging field to the patients and their families. To these aims, TRANSMIT will create a network of seven different countries, among which world-leading basic science and clinical centers of excellence, several industrial partners with up-todate omics technologies, as well as non-profit foundations and associations who care for cancer patients. By creating the critical mass of scientific excellence, TRANSMIT will allow to transfer the current knowledge into the wide field of cancer research, translating scientific and technical advances into the education and training of eleven Early Stage Researchers. TRANSMIT will implement training-through-research dedicated to unravel the metabolic features of cancer, as well as to provide a full portfolio of complementary skills through the creation of a network of basic, translational and industrial laboratories, devoted to a multidisciplinary/multisectorial education of young scientists.

     

    Project Description

    1)      Job Summary (max 1000 characters)

    The ACS project within TRANSMIT aims to develop novel cancer cell models to test metabolic intervention strategies identified by other project partners. Its main objectives are to create a panel of novel, cell-based, three dimensional, in vitro models displaying the metabolic aberrations of human cancers and to characterize suitable readouts which will be used to identify targets for therapeutic intervention. ACS project outputs shall be the production of a panel of novel cell-based models; validation of the novel systems according to industry-compliant principles of utility, reproducibility and robustness; demonstration of model utility using metabolic intervention strategies developed by consortium partners.

    2)      Job description (detailed, max 3000 characters)

    Mounting evidence implicates cancer stem cells (CSCs) as a driving factor in tumourogenesis, lesion growth and metastasis1. ESR8 recruited by partner ACS shall undertake a project aimed at the isolation and characterisation of CSCs and the development of cell-based assays incorporating those stem cells. The project’s objective shall be to build a portfolio of assays from a panel of human donors; the portfolio shall represent different stages of disease development and genetic background. This assay panel shall be characterised in terms of the metabolic aberrations implicated by TRANSMIT project partners in oncogenesis and tumour growth. Thereafter, the assay panel shall be validated according to commercial principles, and will be adapted through application of ACS additive printing and cryopreservation technologies to create a portfolio of analytical tools with potential for commercial exploitation in the field of preclinical drug discovery. The project shall provide extensive training in cell technologies, and in the quality management processes associated with their applications in a commercial environment. The ESR shall also gain insight to and contribute to advancement of knowledge of the role of cancer stem cells in disease progression. The ESR shall extend his /her training through secondments to partners UNIBO and UCL.

     

    3) Subject area of PhD program in which the ESR will be enrolled and PhD program duration

    Duration: 3 years

    4) Host University that will provide the PhD degree

    University of the West of Scotland

    5) PhD program starting date

    !st October 2017

     

    Required Educational Level

    Degree: Masters Degree or similar

    Degree Field: Life science discipline, preferably cell or molecular biology or biochemistry.

    Skills: A suitable background for the open position includes knowledge of cell biology and the uses of cell-based analysis, and the applicant should be able to demonstrate expertise and practical skills in cell culture. In case of equal qualification, candidates with background in a commercial scientific environment will be preferred.

    Languages: Applicant should be fluent in written and spoken English

     

    Applications, in English, should include CV, detailed academic transcripts, a copy of the thesis, a motivation letter and a reference letter, which are all to be submitted by email to Jennifer Garland (jennifer.garland@avanticell.com). Application deadline: 31st May 2017.

     

    *Eligibility: Eligible applicants must have less than 4 years’ research experience (Early Stage Researcher) at the signature of the contract (measured from the time the Master’s degree has been obtained). Eligible applicants must not have been awarded a PhD.

     

    The applicant may be a national of a Member State, of an Associated Country or of any other Third Country.

    The applicant must not have resided in the country where the research training activities take place for more than 12 months in the 3 years immediately prior to the recruitment date and not have carried out their main activity (work, studies, etc.) in that country.

     

    Benefits

    ·         3 year’s employment contract with a leading biotechnology company;

    ·         Scientific training in a strong commercial scientific environment

    ·         Enrollment in a PhD school in a specific area;

    ·         A highly multidisciplinary, cross-cultural and competitive training programme in the field of metabolism in cancer; 

    ·         Secondments and a specific training programme;

    ·         Vacation days/year: 25

     

    Selection criteria

    First selection step: Curriculum evaluation. Numerical scores will be awarded for grading criteria such as study marks, duration of study, scientific publications in peer reviewed journals, reference letters. Only the admitted candidates will be contacted by e-mail for the second selection step.

    Second selection step: Skype interview in which candidates will give a short presentation of their master thesis. This may be followed by a face-to-face interview.

     

    Evaluation period: (if any, specify the duration before the official start date) 30th June 2017

    Qualifications: 
    Degree: Masters Degree or similar; Degree Field: Life science discipline, preferably cell or molecular biology or biochemistry.
    Salary: 
    €52,095
    Employers: 
    AvantiCell Science Ltd (ACS), UK
    Job type: 
    Temporary: 3-year employment contract
    Location: 
    Ayr, South Ayrshire, Scotland, UK
    Contact: 
    Jennifer Garland (jennifer.garland@avanticell.com)
  • Early Stage Researcher (ESR/PhD) in the Marie Skłodowska-Curie ITN European Training Network “TRANSMIT – TRANSlating the role of Mitochondria in Tumorigenesis” (H2020-MSCA-ITN-2016) - ESR 7 (Biocrates Life Sciences AG, Austria)

    Posted: 
    Monday, 20 March 2017
    Expires: 
    Friday, 16 June 2017

    TRANSMIT - TRANSlating the role of Mitochondria in Tumorigenesis

    The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical evidences place mitochondria as key actors in cancer metabolic restructuring, not only because these organelles have a crucial role in the energy and biosynthetic intermediates production but also because occurrence of mutations in metabolic enzymes encoded by both nuclear and mitochondrial DNA has been associated to different types of cancer. TRANSMIT aims to dissect the metabolic remodeling in human cancers, placing the focus on the role of mitochondria and bridging basic research to the improvement/development of therapeutic strategies. Further, TRANSMIT fosters the communication of this emerging field to the patients and their families. To these aims, TRANSMIT will create a network of seven different countries, among which world-leading basic science and clinical centers of excellence, several industrial partners with up-to date omics technologies, as well as non-profit foundations and associations who care for cancer patients. By creating the critical mass of scientific excellence, TRANSMIT will allow to transfer the current knowledge into the wide field of cancer research, translating scientific and technical advances into the education and training of eleven Early Stage Researchers. TRANSMIT will implement training-through-research dedicated to unravel the metabolic features of cancer, as well as to provide a full portfolio of complementary skills through the creation of a network of basic, translational and industrial laboratories, devoted to a multidisciplinary/multisectorial education of young scientists.

     

    Project Description

    1) Job Summary (max 1000 characters)

    BIOCRATES Life Sciences AG – The “Deep Phenotyping” Company, Headquartered in Innsbruck/Austria, is a global leader in the dynamically-growing field of Targeted Metabolomics. Biocrates offers the possibility to identify potential biomarkers for diagnostic investigation as well as drug therapy monitoring. With its mass spectrometry based products the company is providing tools for a comprehensive insight into pathways and metabolic signatures of diseases (such as cancer or neurodegenerative diseases). In our Research & Development department in Innsbruck an early stage researcher (ESR) position is available.

    2) Job description (detailed, max 3000 characters)

    Quantitative analysis of coenzymes in cancer cells

    As central metabolic organelles, mitochondria execute critical biochemical functions for the synthesis of the fundamental cellular components. Coenzymes have a major role in mitochondrial functions including the respiratory chain and biosynthesis of structural components. Analysis of cofactors will improve the understanding of mitochondrial dysfunction and facilitate identification of new therapeutic targets. However, a precise and accurate quantitative analysis of these metabolites is a highly challenging bioanalytical task due to the low intracellular concentrations and instability. Aims of the study are the development of a novel LC-MS/MS based metabolomics method for the quantitative analysis of coenzymes in cancer cell samples and the application of the method to identify the role of coenzymes in different cancer cell types.

    3) Subject area of PhD program in which the ESR will be enrolled and PhD program duration

    The medical science doctorate study program "Ph.D. Scient. Med." is a post-graduate study program and, based on its form, an attendance study with mandatory attendance in accordance with the teaching events specified in the curriculum. The doctorate study "Ph.D. Scient. Med." comprises at least three years and a total workload of 180 ECTS points.

     

    4) Host University that will provide the PhD degree

    The PhD program is hosted by the Paracelsus Medical University Salzburg. As a private university, the Paracelsus Medical University Salzburg does not receive any support from the Ministry of Science and thus charges a study fee.

     

    5) PhD program starting date

    The PhD program is starting in October 2017.

     

    Required Educational Level

    Degree: Master, MSc

    Degree Field: The successful candidates must hold a university degree in analytical chemistry, biochemistry, metabolomics or related fields.

    Skills:

    ·        We are looking for a highly motivated graduate student with proven skills in team working and communication

    ·        The successful candidates must have first research experiences in one of the above mentioned fields.

    ·        First experience with LC-MS/MS based analytical techniques is of advantage

    ·        Mobility to undergo training within the network is mandatory

    Languages: As the ESR will be working in an international and interdisciplinary environment, an excellent command of English (written and oral) is mandatory. Basic knowledge in German is an advantage.                                       

     

    Applications, in English, should include CV, detailed academic transcripts, a copy of the thesis, a motivation letter and a reference letter, which are all to be submitted by email to Dr. Guido Dallmann (guido.dallmann@biocrates.com)

     

    Application deadline: 2017-06-16

     

    The applicant may be a national of a Member State, of an Associated Country or of any other Third Country.

    The applicants not have resided in the country where the research training activities take place for more than 12 months in the 3 years immediately prior to the recruitment date and not have carried out their main activity (work, studies, etc.) in that country.

     

    Benefits

    ·        Enrollment in a PhD school in a specific area

    ·        3-year employment contract (39111 EUR/year including social security and taxes; additionally mobility allowance 7200 EUR/year)

    ·        A highly multidisciplinary, cross-cultural and competitive training program in the field of metabolism in cancer

    ·        Secondments and a specific training program

    ·        Vacation: 25 days/year

     

    Selection criteria

    First selection step: Curriculum evaluation. Numerical scores will be awarded for grading criteria such as study marks, duration of study, scientific publications in peer reviewed journals, reference letters. Only the admitted candidates will be contacted by e-mail for the second selection step.

    Second selection step: Skype or face-to-face interview in which candidates will give a short presentation of their master thesis and of a scientific paper that they will receive three weeks before the interview. 

    Qualifications: 
    Degree: Master, MSc; Degree Field: the successful candidates must hold a university degree in analytical chemistry, biochemistry, metabolomics or related fields.
    Salary: 
    39111 EUR/year including social security and taxes; additionally mobility allowance 7200 EUR/year
    Employers: 
    Biocrates Life Sciences AG, Innsbruck, Austria
    Job type: 
    Temporary: 3-year employment contract
    Location: 
    Innsbruck, Austria
    Contact: 
    Dr. Guido Dallmann (guido.dallmann@biocrates.com)
  • Early Stage Researcher (ESR/PhD) in the European Training Network “TRANSMIT – TRANSlating the role of Mitochondria in Tumorigenesis” (H2020-MSCA-ITN-2016) - ESR 11 (University Hospital of the Paracelsus Medical University Salzburg, Austria)

    Posted: 
    Monday, 20 March 2017
    Expires: 
    Monday, 15 May 2017

    TRANSMIT - TRANSlating the role of Mitochondria in Tumorigenesis

    The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical evidences place mitochondria as key actors in cancer metabolic restructuring, not only because these organelles have a crucial role in the energy and biosynthetic intermediates production but also because occurrence of mutations in metabolic enzymes encoded by both nuclear and mitochondrial DNA has been associated to different types of cancer. TRANSMIT aims to dissect the metabolic remodeling in human cancers, placing the focus on the role of mitochondria and bridging basic research to the improvement/development of therapeutic strategies. Further, TRANSMIT fosters the communication of this emerging field to the patients and their families. To these aims, TRANSMIT will create a network of seven different countries, among which world-leading basic science and clinical centers of excellence, several industrial partners with up-todate omics technologies, as well as non-profit foundations and associations who care for cancer patients. By creating the critical mass of scientific excellence, TRANSMIT will allow to transfer the current knowledge into the wide field of cancer research, translating scientific and technical advances into the education and training of eleven Early Stage Researchers. TRANSMIT will implement training-through-research dedicated to unravel the metabolic features of cancer, as well as to provide a full portfolio of complementary skills through the creation of a network of basic, translational and industrial laboratories, devoted to a multidisciplinary/multisectorial education of young scientists.

     

    ESR11 Impact of ketogenic diet in relation to tumor biology: TRANSMIT is a multi-partner project that intends to mobilise the critical mass of expertise, by linking partners from 10 world-leading basic science and clinical centres of excellence, SMEs with direct interest in mitochondrial cancer metabolism, as well as a non-profit foundation with a 25-year history of advanced training.

    At the Department of Paediatrics at the Paracelsus Medical University in Salzburg - Austria an early stage researcher (ESR) position is available. We are a multi-disciplinary centre of competence whose objective is to offer diagnostic services and research for mitochondrial disorders. Based on our extensive competence in mitochondrial biology we also established a research program on tumor metabolism

     

    Job description: A bulk of evidence has been accumulated in recent years demonstrating that neoplastic development is tightly linked with and dependent on mitochondrial metabolism.  The ESR will directly target the increased glycolysis and low OXPHOS activity of solid cancers by dietary intervention. Due to the metabolic adaptability of cancer cells, it may be necessary to combine agents that target different metabolic pathways to achieve high therapeutic efficacy. Targeting of metabolic reprogramming in cancer cells should render them more sensitive to classical chemo or radiation therapy and would likely permit reduced drug doses or duration of treatment. Different diets in combination with chemotherapeutics will be used to treat mice with xenografts. The effect of the treatments on important parameters of tumour progression will be determined. The studies will reveal if the success of the dietary intervention depends on specific alterations of tumor cell metabolism.

    PhD program in which the ESR will be enrolled: The ESR can enroll for PhD studies in medical sciences (http://www.pmu.ac.at/en/medicalsciencephd.html) at the Paracelsus Medical Universtiy (www.pmu.ac.at). The qualification objectives of the "Ph.D. Scient. Med." correspond to the Level 8 of the European qualification framework for lifelong learning. The knowledge, skills and competences acquired after the successful completion of the doctorate study permit to the graduates to exercise the scientific research as a profession and they are thus in a position to fulfil the specific scientific as well as the professional requirements in this area of activity.

    Alternatively the ESR has the possibility to enroll in the Doctoral program of the Faculty of Natural Sciences of the University Salzburg (www.uni-salzburg.at).

     

    Benefits

    ·         The ESR will be appointed as Marie Sklodowska-Curie Fellow with a 3-year employment contract (38.5 hours per week) at 39100 euro/year, 600 euro/month mobility allowance and family allowance depending on family situation. The net salary results from deducting all compulsory (employer/employee) social security contributions as well as direct taxes (e.g. income tax) from the gross amounts. The rate indicated here is for researchers devoting themselves to their project on a full-time basis.

    ·         A highly multidisciplinary, cross-cultural and competitive training program in the field of metabolism in cancer.

    ·         The appointment is offered in conjunction with an enrollment in a PhD program. PhD tuition fees for the candidate are covered and the research project is aimed at defending a thesis and obtaining a PhD degree.

    ·         In addition to the scientific project, the ESR will benefit from further continuing training, which includes summer schools and secondments, a variety of training courses as well as transferable skill courses, active participation in workshops and conferences, and exposure to SME(s) and universities from the different European countries.

    ·         Vacation days/year: 25 days

    Starting date: Summer/autumn 2017 but never later than January 1st, 2018.

     

    Eligibility criteria

    Required Educational Level: Master, Msc

    Degree Field: The successful candidates must be in possession/just finishing a university Masters degree in chemistry, biology, genetics, molecular biology, biochemistry, pharmacy, medicine, or related fields.

    Skills: A background in cancer metabolism or experience with in vivo models would be an advantage.

    Languages:  As the ESRs will be working in an international and interdisciplinary environment, an excellent command of English (written and oral) is mandatory.  Basic knowledge in German is an advantage

    Status ESR: At the date of recruitment – the ‘early stage researcher’ has to be in the first four years (full time equivalent research experience) of his/her research career and not have been awarded a doctoral degree.

    Trans-national mobility (i.e. move from one country to another) is an essential requirement of MSCA-ITN. The ESR can be of any nationality. At the time of recruitment by the host organisation, he/she must not have resided or carried out his/her main activity (work, studies, etc) in the country of the host organisation for more than 12 months in the three years immediately before the reference date. Compulsory national service and/or short stays such as holidays are not taken into account.

     

    Applications, in English, should include CV, detailed academic transcripts, a copy of the thesis, a motivation letter and a reference letter, which are all to be submitted by email to b.kofler@salk.at

     

    Selection criteria

    First selection step: Curriculum evaluation. Numerical scores will be awarded for grading criteria such as study marks, duration of study, scientific publications in peer reviewed journals, reference letters. Only the admitted candidates will be contacted by e-mail for the second selection step.

    Second selection step: Skype or face-to-face interview in which candidates will give a short presentation of their master thesis and of a scientific paper that they will receive a week before the interview.

     

    The University seeks to increase the number of its female faculty and staff members. Therefore qualified women are strongly encouraged to apply. In case of equal qualification, female candidates will be given preference unless reasons specific to an individual male candidate tilt the balance in his favour.

     

    Deadline for submission: 15th of May 2017, until position is filled

    This project has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No.: 722605

     

    Applications to:

    a.o.Univ. Prof. Dr. Barbara Kofler

    Research Program for Receptor Biochemistry and Tumor Metabolism

    Department of Pediatrics

    Paracelsus Medical University Salzburg

    Muellner Hauptstr. 48

    A-5020 Salzburg

    Austria

    b.kofler@salk.at

    Qualifications: 
    Required Educational Level: Master, Msc; Degree Field: the successful candidates must be in possession/just finishing a university Masters degree in chemistry, biology, genetics, molecular biology, biochemistry, pharmacy, medicine, or related fields.
    Salary: 
    39100 euro/year, 600 euro/month mobility allowance and family allowance depending on family situation
    Employers: 
    University Hospital of the Paracelsus Medical University Salzburg, Austria
    Job type: 
    Temporary: 3-year employment contract
    Location: 
    Salzburg, Austria
    Contact: 
    Prof. Dr. Barbara Kofler (b.kofler@salk.at)
  • Early Stage Researcher (ESR/PhD) in the Marie Skłodowska-Curie ITN European Training Network “TRANSMIT – TRANSlating the role of Mitochondria in Tumorigenesis” (H2020-MSCA-ITN-2016) - ESR 4 (University of Cambridge, UK)

    Posted: 
    Monday, 20 March 2017
    Expires: 
    Sunday, 30 April 2017

    TRANSMIT - TRANSlating the role of Mitochondria in Tumorigenesis

    The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical evidences place mitochondria as key actors in cancer metabolic restructuring, not only because these organelles have a crucial role in the energy and biosynthetic intermediates production but also because occurrence of mutations in metabolic enzymes encoded by both nuclear and mitochondrial DNA has been associated to different types of cancer. TRANSMIT aims to dissect the metabolic remodeling in human cancers, placing the focus on the role of mitochondria and bridging basic research to the improvement/development of therapeutic strategies. Further, TRANSMIT fosters the communication of this emerging field to the patients and their families. To these aims, TRANSMIT will create a network of seven different countries, among which world-leading basic science and clinical centers of excellence, several industrial partners with up-todate omics technologies, as well as non-profit foundations and associations who care for cancer patients. By creating the critical mass of scientific excellence, TRANSMIT will allow to transfer the current knowledge into the wide field of cancer research, translating scientific and technical advances into the education and training of eleven Early Stage Researchers. TRANSMIT will implement training-through-research dedicated to unravel the metabolic features of cancer, as well as to provide a full portfolio of complementary skills through the creation of a network of basic, translational and industrial laboratories, devoted to a multidisciplinary/multisectorial education of young scientists.

     

    ESR (Early Stage Researcher) position for 36 months at Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK

    The Frezza laboratory focuses on understanding the role of the mitochondrial enzyme and component of the tricarboxylic acid (TCA) cycle Fumarate Hydratase in tumorigenesis. We have recently demonstrated that fumarate, accumulated in FH-deficient cells, elicits a powerful epigenetic reprogramming that leads to the suppression of miRNA200, and induction of epithelial–to-mesenchymal transition (Sciacovelli et al, Nature 2016). This epigenetic and phenotypic switch makes FH-deficient cells more motile and invasive, predisposing to metastasis. Although we demonstrated that fumarate has a role as epigenetic modifier, its effects on chromatin structure and function are still unknown. This project will help to elucidate the link between TCA cycle dysfunction, accumulation of fumarate, and downstream epigenetic changes involved in tumorigenesis. To this aim the ESR will investigate the hypothesis that fumarate controls the activity of histone and DNA demethylases involved in DNA and histone methylation, causing broad epigenetic changes. The ESR will first generate a 3D cellular model of FH-deficiency by deleting FH in human renal cell lines obtained using CRISPR technology. He/she will then perform comprehensive subcellular metabolomics analyses to study the metabolic changes induced by the loss of FH in a compartment-specific manner, focusing in particular on the accumulation of fumarate in the nucleus. Then, the ESR will perform an extensive epigenetic analysis aimed at understanding how fumarate modulates genes expression and chromatin structure by altering DNA methylation and histone marks deposition. To assess DNA methylation, genome scale bisulfite sequencing and liquid chromatography analyses will be performed. Further, ESR will also perform Chip-bisulfite sequencing analyses to evaluate changes in histones binding to chromatin and their association to methylated DNA. These epigenetic changes will be merged with RNA-seq experiments to find the link between epigenetic modification and gene expression.

    Subject area of PhD program in which the ESR will be enrolled and PhD program duration: 3-year enrollment to a PhD Medical Science

    Host University that will provide the PhD degree: University of Cambridge 

    PhD program starting date: 01/10/2017 

    Required Educational Level

    Degree: Applicants should hold a Masters level Degree in Biological Sciences in the field of Biochemistry, Cell Biology, or Cancer Biology.

    Skills: The ideal candidate should be familiar with the field of cancer metabolism and have a clear understanding of cellular metabolism and mitochondrial physiology. He/she will have proven experience with cell culture and several lab techniques, including western blotting, molecular biology. The ideal candidate should also be familiar with the basics bioinformatics tools and be familiar with software for data analysis. A distinct advantage will be previous experience with metabolomics experiments and work in the field of caner metabolism, and familiarity with epigenetics.

    Additional requirements: Team spirit, good communication skills, and trans-national mobility

    Languages: English

     

    Eligibility: The applicants must be in possession of a degree in Biological sciences at the date of recruitment

    - an ‘early stage researcher’ (i.e. in the first four years of his/her research career and not have a doctoral degree). The applicants must not have resided in the country where the research training activities take place for more than 12 months in the 3 years immediately prior to the recruitment date and not have carried out their main activity (work, studies, etc.) in that country. 

    The applicant may be a national of a Member State, of an Associated Country or of any other Third Country.

     

    Benefits

    •         Enrollment in a PhD school in Medical Science 

    •         3-year employment contract and a salary of 44,895 Euro per annum augmented by a mobility allowance of 7,200 Euro per annum

    •         A highly multidisciplinary, cross-cultural and competitive training program in the field of metabolism in cancer 

    •         Secondments and a specific training program 

    •         Vacation days/year: 33 days + bank holidays

     

    Selection criteria

    Applications, in English, should include a CV, a covering letter, detailed academic transcripts, a copy of the master’s thesis and a letter of reference - all to be submitted by email to Christine Fox (cf208@MRCCU.cam.ac.uk). Application deadline: 30 April 2017.

    First selection step: Curriculum evaluation. Numerical scores will be awarded for various grading criteria such as study marks obtained, duration of study, scientific publications in peer reviewed journals, reference letter. Only those candidates who are shortlisted from this step will be contacted by e-mail for the second selection step.

    Second selection step: Skype or face-to-face interviews in which candidates will be required to give a short presentation of their master’s thesis and to discuss a scientific paper that they will receive before the interview. The interview panel will include the principal investigator and other members of the host laboratory.  

    Qualifications: 
    Masters level Degree in Biological Sciences in the field of Biochemistry, Cell Biology, or Cancer Biology.
    Salary: 
    44,895 Euro per annum augmented by a mobility allowance of 7,200 Euro per annum
    Employers: 
    University of Cambridge, UK
    Job type: 
    Temporary: 3-year employment contract
    Location: 
    Cambridge, UK
    Contact: 
    Christine Fox (cf208@MRCCU.cam.ac.uk).

Pages